Arrowhead Pharmaceuticals IncArrowhead Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This Sustainability rating for Arrowhead Pharmaceuticals Inc represents its transparency towards the United Nations Sustainable Development Goals. Other companies in the rating peer group for Arrowhead Pharmaceuticals Inc are shown below. Full ESG analysis of Arrowhead Pharmaceuticals Inc can be accessed by logging in.

Arrowhead Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.3; made up of an environmental score of 2.7, social score of 3.4 and governance score of 6.7.

SDG Transparency Score for Arrowhead Pharmaceuticals Inc 
Low
0 - 3

4.3

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Arrowhead Pharmaceuticals Inc 
2.7

Environmental

3.4

Social

6.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
910Vaxcyte Inc
4.4
High
910Yield10 Bioscience Inc
4.4
High
951Arrowhead Pharmaceuticals Inc
4.3
High
951Cerecor Inc
4.3
High
951Allergy Therapeutics PLC
4.3
High
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Arrowhead Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Arrowhead Pharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Arrowhead Pharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Arrowhead Pharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does Arrowhead Pharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Arrowhead Pharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Arrowhead Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Sorry!

Failed to process!